M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia.

Citation data:

Neuron, ISSN: 1097-4199, Vol: 88, Issue: 4, Page: 762-73

Publication Year:
Usage 85
Abstract Views 80
Link-outs 5
Captures 13
Readers 8
Exports-Saves 5
Mentions 1
References 1
Social Media 23
Shares, Likes & Comments 15
Tweets 8
Citations 48
Citation Indexes 48
Shen, Weixing; Plotkin, Joshua L; Francardo, Veronica; Ko, Wai Kin D; Xie, Zhong; Li, Qin; Fieblinger, Tim; Wess, Jürgen; Neubig, Richard R; Lindsley, Craig W; Conn, P Jeffrey; Greengard, Paul; Bezard, Erwan; Cenci, M Angela; Surmeier, D James Show More Hide
Elsevier BV
Most Recent Tweet View All Tweets
article description
A balanced interaction between dopaminergic and cholinergic signaling in the striatum is critical to goal-directed behavior. But how this interaction modulates corticostriatal synaptic plasticity underlying learned actions remains unclear--particularly in direct-pathway spiny projection neurons (dSPNs). Our studies show that in dSPNs, endogenous cholinergic signaling through M4 muscarinic receptors (M4Rs) promoted long-term depression of corticostriatal glutamatergic synapses, by suppressing regulator of G protein signaling type 4 (RGS4) activity, and blocked D1 dopamine receptor dependent long-term potentiation (LTP). Furthermore, in a mouse model of L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia (LID) in Parkinson's disease (PD), boosting M4R signaling with positive allosteric modulator (PAM) blocked aberrant LTP in dSPNs, enabled LTP reversal, and attenuated dyskinetic behaviors. An M4R PAM also was effective in a primate LID model. Taken together, these studies identify an important signaling pathway controlling striatal synaptic plasticity and point to a novel pharmacological strategy for alleviating LID in PD patients.